Specialty shop BioLumina promotes Jones to president

Share this article:
Ane Jones
Ane Jones
Omnicom specialty agency BioLumina promoted Ane Jones to president from managing director. It's the latest management change at the agency and its bigger sibling, Harrison & Star.

Jones is now responsible for the day-to-day operations of BioLumina, building on her experience running the account side and her ability to attract new business. Those qualities, along with Jones' knowledge of oncology and specialty markets, make her a “strong choice” for president, said agency CEO Ty Curran in a statement.

BioLumina roster clients include Merck's oncology franchise, as well as Eisai's oncology pipeline. H&S handles work for Avastin, among other brands from Roche's Genentech unit.

Jones' appointment comes on the heels of Curran's succession at H&S in March, from president to CEO. In his place is Mardene Miller, a 14-year H&S veteran who had been SVP/managing director.

Miller assumed day-to-day operations of the agency from Curran, who had run the shop the last eight years. Curran is now CEO of H&S and BioLumina. Both are full-service professional healthcare ad agencies operating under the Medical Specialist Group umbrella, a unit of Omnicom's Diversified Agency Services.

The leadership succession plan also extends to H&S co-founder Larry Star. Last year Star handed over the managerial reigns to Curran and became chairman. He's due to step down from that position at year's end but will remain on the executive leadership committee.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...